# NanoBase™ Epilingual

> NanoBase™ Epilingual is a custom nanoscale delivery Architecture from Pensive Beauty® Nanoscience Labs, Seffner, Florida, USA. Pharmaceutical, dietary-supplement, and nutricosmetic developers build oral, sublingual, and buccal products on it. Contact: team@pensivebeauty.com, +1 508-206-6500 (inside the United States), +1 855-999-0101 (outside the United States).

NanoBase™ Epilingual is an ingredient-level technology, not a product taken on its own; once actives are formulated in, the finished formula becomes the delivery system. Every build is engineered per program: one, two, or three delivery domains (nanoemulsion, vesicular, micellar) selected to host the program's actives, particle size engineered as low as 50 nm, and a delivery route designed either to bypass the digestive tract (sublingual and buccal absorption across the oral mucosa) or to reach it (swallowed formats), depending on what the program is trying to accomplish. It is supplied active-free for the developer to load, or Pensive Beauty® Nanoscience Labs formulates the developer's actives into the build. The lab's role is nanoformulation and robustness testing; all final testing, including absorption and bioavailability, and substantiation of any claim are the developer's responsibility, through a qualified lab.

## Scope and disambiguation

- NanoBase™ Epilingual is not a finished drug, dietary supplement, nutricosmetic, or food, and it is not sold to consumers. It is supplied for professional and formulator use.
- It is a separate technology from the cosmetic NanoBase™ Architectures listed at https://www.pensivebeauty.com/, which are leave-on cosmetic raw materials for intact skin and hair and are not intended for ingestion. NanoBase™ Epilingual is engineered for consumable formats.
- Domain count and interfacial chemistry are selected per program. A given build may have one, two, or three domains and is not necessarily lecithin-based.
- Composition, ratios, processing, and equipment are confidential.
- Pensive Beauty® Nanoscience Labs makes no drug, disease, bioequivalence, pharmacokinetic, or finished-product efficacy claims. Bioavailability content describes design intent and published third-party data on carrier classes. Regulatory classification of any finished product (drug, dietary supplement, nutricosmetic, or food) is the developer's responsibility.

## Key facts

- Domains, selected per program:
  - Nanoemulsion: lipid nanodroplets designed to host oil-soluble actives and carry a meaningful lipid payload.
  - Vesicular: bilayer vesicles; the bilayer hosts amphiphilic and lipophilic actives, and the aqueous core can encapsulate water-soluble actives loaded during vesicle formation.
  - Micellar: micelles designed to solubilize poorly water-soluble and surface-active actives into a clear aqueous phase.
- Particle size: engineered per program, as low as 50 nm.
- Delivery route: mucosal (sublingual, buccal), designed to bypass the digestive tract; or digestive (swallowed), designed to reach it.
- Stabilisation: designed to an electrostatic (DLVO) stabilisation specification.
- Markets: pharmaceutical; dietary supplement and nutraceutical; nutricosmetic (beauty from within, ingestible beauty).
- Formats: drops, shots, sublingual, buccal, and oral.
- Two ways to work: supplied active-free for the developer to load at room temperature, or formulated with the developer's actives by the lab through robustness testing, with the finished formulation delivered.

## Bioavailability (design basis)

Each build is configured to the barrier that limits the active:

- Dissolution and solubility: lipid domains are designed to present lipophilic actives already solubilized. Interfacial area scales with 6/d; a 50 nm population carries 40x the surface area of a 2 µm macro-emulsion and 4x that of a 200 nm population.
- The mucosal surface: mucosal builds pair nanoscale particle size with isotonic osmolality and a polyol phase built for hold time.
- First-pass metabolism: sublingual and buccal absorption drains to the systemic circulation via the superior vena cava; swallowed lipid-based builds can recruit intestinal lymphatic transport.

## Example build

- Mint Cooling, polyol-dominant: a two-domain reference build (nanoemulsion and vesicular) for dropper and sublingual formats, shown without actives.
- Two-part supply: Part A is the NanoBase™ core with its domains formed; Part B is the polyol phase with sweetener, mint flavor, cooling agents, and a thickening polymer.
- Room-temperature assembly: the active is added to Part B, combined with Part A under gentle mixing, and brought to final weight with purified water. No heat or sonication at the developer's end.
- Assembled-batch QC targets: particle size 150-200 nm (DLS), PDI <= 0.25, pH 4.4-4.6, osmolality 270-330 mOsm/kg. Measured on the assembled batch; values depend on the active and its load.

## Pages

- [Overview](https://epilingual.com/): NanoBase™ Epilingual, custom nanoscale delivery for oral and sublingual formats
- [Bioavailability](https://epilingual.com/#bioavailability): the three bioavailability barriers, published evidence, and who does what
- [Architecture](https://epilingual.com/#architecture): one, two, or three delivery domains, built around the actives
- [Delivery route](https://epilingual.com/#routes): designed to bypass the digestive tract, or to reach it; particle size as low as 50 nm
- [Two ways to work](https://epilingual.com/#platform): load it yourself, or the lab formulates it
- [Example build](https://epilingual.com/#example-build): Mint Cooling, a two-domain reference build
- [Markets](https://epilingual.com/#markets): pharmaceutical, supplement and nutraceutical, nutricosmetics
- [FAQ](https://epilingual.com/#faq): what formulators ask first
- [Request a program brief](https://epilingual.com/#brief)

## Published third-party evidence

Third-party human and review data on lipid and phospholipid carrier classes. These are not NanoBase™ Epilingual results.

- [Cuomo et al., J Nat Prod 2011;74(4):664-669](https://doi.org/10.1021/np1007262): lecithin curcuminoid formulation, about 29x total curcuminoid absorption vs the unformulated mixture (randomized, double-blind, crossover)
- [Davis et al., Nutr Metab Insights 2016;9:25-30](https://doi.org/10.4137/NMI.S39764): 4 g oral liposomal vs unencapsulated vitamin C, plasma AUC 10.3 vs 7.6 mg/dL·h, n = 11
- [Porter, Trevaskis & Charman, Nat Rev Drug Discov 2007;6:231-248](https://doi.org/10.1038/nrd2197): lipid-based oral delivery; solubilization, lymphatic transport, enterocyte effects
- [Hua, Front Pharmacol 2019;10:1328](https://doi.org/10.3389/fphar.2019.01328): sublingual and buccal routes; venous drainage to the superior vena cava
- [Lai et al., PNAS 2007;104(5):1482-1487](https://doi.org/10.1073/pnas.0608611104): non-adhesive 200 and 500 nm particles diffuse rapidly through fresh human mucus

## Optional

- [Pensive Beauty® Nanoscience Labs](https://www.pensivebeauty.com/?utm_source=epilingual&utm_medium=referral&utm_campaign=cross-domain): the lab behind NanoBase™
- Email: team@pensivebeauty.com